fb-pixel Skip to main content

Quartet Medicine raises $17m to develop treatments for chronic pain and inflammation

Quartet Medicine, a Cambridge biotechnology company seeking to develop treatments for chronic pain and inflammation, said Thursday that it has raised $17 million in a Series A financing.

The financing was led by Atlas Venture with Novartis Venture Funds, Pfizer Venture Investment, and Partners Innovation Fund joining the funding round, Quartet said in a press release.

Bruce Booth, chairman of Quartet and partner at Atlas Venture, said in a statement, “We are capitalizing on recent advances in human genetics that are revealing new mechanisms and, ultimately, novel targets for drug discovery and development in the challenging and underserved therapeutic area of chronic pain.”


According to the company’s release, Quartet was co-founded in late 2013 by Kevin Pojasek, while working as an entrepreneur-in-residence at Atlas Venture, along with Clifford Woolf, MD, of Harvard Medical School and Boston Children’s Hospital, and Kai Johnsson of École Polytechnique Fédérale de Lausanne.